Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

This is a clinical practice guideline for patients with stage IV non-small cell lung cancer (NSCLC) without effectively targeted driver alterations. The guideline examines systemic therapy treatment options that are available for this patient population, taking into consideration the subtype of cancer. Treatment options discussed include single-agent pembrolizumab, pembrolizumab/carboplatin/pemetrexed, and atezolizumab/carboplatin/nab-paclitaxel.